Literature DB >> 2199627

Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man.

F Fraschini1, F Scaglione, M Falchi, S Dugnani, M Mezzetti, F Cicchetti, G Alfano, G P Pintucci.   

Abstract

Augmentin (875 amoxicillin and 125 mg potassium clavulanate) was administered orally to patients with chronic bronchitis. Concentrations of amoxicillin and clavulanic acid were measured in serum, sputum and urine. Peak serum levels for amoxicillin of 11.23 +/- 2.61 micrograms/ml were observed at 2 hours and for clavulanic acid of 2.55 +/- 0.54 micrograms/ml at 1 hour. After 9 hours, 50% of the amoxicillin and 39% of the clavulanic acid had been renally excreted. The peak sputum concentration of amoxicillin was 1.31 +/- 0.42 micrograms/ml at 4 hours and of clavulanate was 0.79 +/- 0.23 micrograms/ml at 2 hours. Patients awaiting surgery received an oral dose of augmentin as above. Samples of lung, tonsil, middle ear mucosa and prostate were obtained and tissue concentrations of both compounds measured. Peak levels of amoxicillin ranged from 0.87 micrograms/g (tonsil) to 2.56 micrograms/g (lung) and of clavulanic acid from 0.20 micrograms/g (prostate) to 0.56 micrograms/g (lung) between 3 and 4 hours after dosing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199627     DOI: 10.1080/1120009x.1990.11739013

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

1.  In vitro assessment of the effect of clavulanic acid at concentrations achieved in human serum on the bactericidal activity of amoxicillin at physiological concentrations against Staphylococcus aureus: implications for dosage regimens.

Authors:  L Aguilar; M Martín; I P Balcabao; M L Gómez-Lus; R Dal-Ré; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against Streptococcus pneumoniae.

Authors:  M Martín; M L Gómez-Lus; L Aguilar; P Martínez; M J Giménez; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation.

Authors:  I P Balcabao; L Aguilar; M Martín; Y García; R Dal-Ré; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

4.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

5.  Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.

Authors:  C E Thorburn; S J Molesworth; R Sutherland; S Rittenhouse
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 6.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.

Authors:  Arantxa Isla; Andrés Canut; Alicia R Gascón; Alicia Labora; Bruno Ardanza-Trevijano; Maria Angelés Solinís; Jose Luis Pedraz
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Susceptibility of β-Lactam Antibiotics and Genetic Mutation of Drug-Resistant Mycobacterium tuberculosis Isolates in Korea.

Authors:  Sanghee Park; Jihee Jung; Jiyeon Kim; Sang Bong Han; Sungweon Ryoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-05-19

9.  Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease.

Authors:  Marjolein Brusse-Keizer; Paul VanderValk; Rogier W van der Zanden; Lars Nijdam; Job van der Palen; Ron Hendrix; Kris Movig
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.